Patents by Inventor George Stuart Cockerill

George Stuart Cockerill has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160339027
    Abstract: A pharmaceutical formulation comprising the compound of formula
    Type: Application
    Filed: August 3, 2016
    Publication date: November 24, 2016
    Applicant: NOVARTIS AG
    Inventors: Malcolm Clive Carter, George Stuart Cockerill, Karen Elizabeth Lackey, Stephen Barry Guntrip, Kathryn Jane Smith
  • Publication number: 20160051551
    Abstract: A pharmaceutical formulation comprising the compound of formula
    Type: Application
    Filed: October 20, 2015
    Publication date: February 25, 2016
    Applicant: NOVARTIS AG
    Inventors: Malcolm Clive Carter, George Stuart Cockerill, Karen Elizabeth Lackey, Stephen Barry Guntrip, Kathryn Jane Smith
  • Patent number: 9199973
    Abstract: A pharmaceutical formulation comprising the compound of formula
    Type: Grant
    Filed: November 10, 2014
    Date of Patent: December 1, 2015
    Assignee: Novartis AG
    Inventors: Malcolm Clive Carter, George Stuart Cockerill, Karen Elizabeth Lackey
  • Publication number: 20150065527
    Abstract: A pharmaceutical formulation comprising the compound of formula
    Type: Application
    Filed: November 10, 2014
    Publication date: March 5, 2015
    Inventors: Malcolm Clive Carter, George Stuart Cockerill, Karen Elizabeth Lackey
  • Patent number: 8912205
    Abstract: A pharmaceutical formulation comprising the compound of formula
    Type: Grant
    Filed: July 16, 2013
    Date of Patent: December 16, 2014
    Assignee: GlaxoSmithKline LLC
    Inventors: Malcolm Clive Carter, George Stuart Cockerill, Karen Elizabeth Lackey
  • Publication number: 20130310562
    Abstract: A pharmaceutical formulation comprising the compound of formula
    Type: Application
    Filed: July 16, 2013
    Publication date: November 21, 2013
    Applicant: GlaxoSmithKline LLC
    Inventors: Malcolm Clive Carter, George Stuart Cockerill, Karen Elizabeth Lackey
  • Patent number: 8513262
    Abstract: A process for the preparation of a compound of formula (I) comprising the steps: (a) reacting a compound of formula (II) wherein L and L? are suitable leaving groups, with a compound of formula (III) UNH2??(III) to prepare a compound of formula (IV) and subsequently (b) substituting the group R1 by replacement of the leaving group L?.
    Type: Grant
    Filed: January 22, 2010
    Date of Patent: August 20, 2013
    Assignee: GlaxoSmithKline LLC
    Inventors: Malcolm Clive Carter, George Stuart Cockerill, Karen Elizabeth Lackey
  • Publication number: 20110053934
    Abstract: A derivative, which is useful as a ret kinase inhibitor is described herein. The described invention also includes methods of using the same in the treatment of diseases mediated by inappropriate ret kinase activity.
    Type: Application
    Filed: January 21, 2010
    Publication date: March 3, 2011
    Applicant: GLAXOSMITHKLINE LLC
    Inventors: RICHARD MARTYN ANGELL, IAN ROBERT BALDWIN, GEORGE STUART COCKERILL, STEPHEN SEAN FLACK, KAREN ELIZABETH LACKEY, PHILIP ALAN SKONE, KATHRYN JANE SMITH
  • Publication number: 20100120804
    Abstract: A process for the preparation of a compound of formula (I) comprising the steps: (a) reacting a compound of formula (II) wherein L and L? are suitable leaving groups, with a compound of formula (III) UNH2 ??(III) to prepare a compound of formula (IV) and subsequently (b) substituting the group R1 by replacement of the leaving group L?.
    Type: Application
    Filed: January 22, 2010
    Publication date: May 13, 2010
    Inventors: Malcom Clive Carter, George Stuart Cockerill, Stephen Barry Guntrip, Karen Elizabeth Lackey, Kathryn Jane Smith
  • Patent number: 7507741
    Abstract: Heteroaromatic compounds are described, methods for their preparation, pharmaceutical compositions containing them, methods of use, and their use in medicines. In particular, the invention relates to quinazoline and pyridopyrimidine derivatives which exhibit protein tyrosine kinase inhibition.
    Type: Grant
    Filed: August 1, 2007
    Date of Patent: March 24, 2009
    Assignee: SmithKline Beecham Corporation
    Inventors: George Stuart Cockerill, Karen Elizabeth Lackey
  • Patent number: 7432289
    Abstract: Compounds of formula (I): or pharmaceutically acceptable salts or solvates thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors.
    Type: Grant
    Filed: October 16, 2002
    Date of Patent: October 7, 2008
    Assignee: Glaxo Group Limited
    Inventors: Richard Martyn Angell, Nicola Mary Aston, Paul Bamborough, Mark James Bamford, George Stuart Cockerill, Stephen Sean Flack, Dramane Ibrahim Lainé, Suzanne Joy Merrick, Kathryn Jane Smith, Ann Louise Walker
  • Patent number: 7396843
    Abstract: Compounds of formula (I): or pharmaceutically acceptable salts or solvates thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors.
    Type: Grant
    Filed: October 16, 2002
    Date of Patent: July 8, 2008
    Assignee: Glaxo Group Limited
    Inventors: Richard Martyn Angell, Nicola Mary Aston, Paul Bamborough, Mark James Bamford, George Stuart Cockerill, Suzanne Joy Merrick, Ann Louise Walker
  • Patent number: 7384963
    Abstract: Compounds of formula (I), wherein R1 is a phenyl group which may be optionally substituted; R2 is selected from hydrogen, C1-6 alkyl and (CH2)p—C3-7cycloalkyl; R3 is the group: (Formula II), R4 is selected from hydrogen and C1-4 alkyl; U is selected from methyl and halogen; X and Y are each selected independently from hydrogen, methyl and halogen; m is selected from 0, 1, 2, 3 and 4, and may be optionally substituted with up to two groups selected independently from C1-6 alkyl; n is selected from 0, 1 and 2; p is selected from 0, 1 and 2; or pharmaceutically acceptable salts or solvates thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors
    Type: Grant
    Filed: October 16, 2002
    Date of Patent: June 10, 2008
    Assignee: Glaxo Group Limited
    Inventors: Richard Martyn Angell, Paul Bamborough, George Stuart Cockerill, Ann Louise Walker
  • Publication number: 20080114008
    Abstract: Compounds of formula (I) are found to be active in inhibiting replication of flaviviridac Formula (I) wherein: X represents a direct bond or a moiety -L-NR—, wherein R is hydrogen or C1-C4 alkyl, and L represents a C1-C4alkylene, C6-C10 aryl or 5- to 10-membered heteroaryl moiety; either R1 and R2, together with the N atom to which they are attached, form a 5- to 10-membered heterocyclyl group or a 5- to 10-membered heteroaryl group, or R1 represents hydrogen, C6-C10 aryl, C1-C4 alkyl or C1-C4 hydroxyalkyl and R2 represents C6-C10 aryl, C1-C4 alkyl or C1-C4 hydroxyalkyl; and R3 represents a C6-C10 aryl, C3-C6 carbocyclyl, 5- to 10-membered heteroaryl or 5- to 10-membered heterocyclyl moiety, said aryl, carbocyclyl, heteroaryl and heterocyclyl groups being unsubstituted or substituted by 1, 2 or 3 substituents selected from halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, hydroxy, thiol, —NH2, C1-C4 hydroxyalkyl, C1-C4 thioalkyl and C1-C4aminoalkyl substituents.
    Type: Application
    Filed: January 30, 2006
    Publication date: May 15, 2008
    Applicant: ARROW THERAPEUTICS LIMITED
    Inventors: George Stuart Cockerill, Stephen Sean Flack, Neil Mathews, James Iain Salter
  • Patent number: 7309800
    Abstract: Compounds of formula (I): or pharmaceutically acceptable salts or solvates thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors.
    Type: Grant
    Filed: November 3, 2006
    Date of Patent: December 18, 2007
    Assignee: Glaxo Group Limited
    Inventors: Richard Martyn Angell, Nicola Mary Aston, Paul Bamborough, Mark James Bamford, George Stuart Cockerill, Stephen Sean Flack, Dramane Ibrahim Lainé, Ann Louise Walker
  • Patent number: 7265123
    Abstract: Heteroaromatic compounds are described, methods for their preparation, pharmaceutical compositions containing them, methods of use, and their use in medicines. In particular, the invention relates to quinazoline and pyridopyrimidine derivatives which exhibit protein tyrosine kinase inhibition.
    Type: Grant
    Filed: November 21, 2006
    Date of Patent: September 4, 2007
    Assignee: SmithKline Beecham Corporation
    Inventors: George Stuart Cockerill, Karen Elizabeth Lackey
  • Patent number: 7208629
    Abstract: Compounds of formula (I): wherein when m is 0 to 4 R1 is selected from C1–6alkyl, C3–7cycloalkyl, C2–6alkenyl, —SO2NR4R5, —CONR4R5 and —COOR4; and when m is 2 to 4 R1 is additionally selected from C1–6alkoxy, hydroxy, NR4R5, —NR4SO2R5, —NR4SOR5, —NR4COR5, and —NR4CONR4R5; R2 is selected from hydrogen, C1–6alkyl and —(CH2)n-C3–7cycloalkyl; R3 is the group —CO—NH—(CH2)p-R6; U is selected from methyl and halogen; W is selected from methyl and chlorine; V and Y are each selected independently from hydrogen, methyl and halogen; m is selected from 0, 1, 2, 3 and 4 wherein each carbon atom of the resulting carbon chain may be optionally substituted with one or two groups selected independently from C1–6alkyl; n is selected from 0, 1, 2 and 3; p and r are independently selected from 0, 1 and 2; s is selected from 0, 1 and 2; or pharmaceutically acceptable salts or solvates thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors
    Type: Grant
    Filed: October 16, 2002
    Date of Patent: April 24, 2007
    Assignee: Glaxo Group Limited
    Inventors: Richard Martyn Angell, Nicola Mary Aston, Paul Bamborough, George Stuart Cockerill, Suzanne Joy Merrick, Kathryn Jane Smith, Ann Louise Walker
  • Patent number: 7189734
    Abstract: Heteroaromatic compounds are described, methods for their preparation, pharmaceutical compositions containing them, methods of use, and their use in medicines. In particular, the invention relates to quinazoline and pyridopyrimidine derivatives which exhibit protein tyrosine kinase inhibition.
    Type: Grant
    Filed: April 7, 2006
    Date of Patent: March 13, 2007
    Assignee: SmithKline Beecham Corporation
    Inventors: George Stuart Cockerill, Karen Elizabeth Lackey
  • Patent number: 7183297
    Abstract: Compounds of formula (I): or pharmaceutically acceptable salts or solvates thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors.
    Type: Grant
    Filed: October 16, 2002
    Date of Patent: February 27, 2007
    Assignee: Glaxo Group Limited
    Inventors: Richard Martyn Angell, Nicola Mary Aston, Paul Bamborough, Mark James Bamford, George Stuart Cockerill, Stephen Sean Flack, Dramane Ibrahim Lainé, Ann Louise Walker
  • Patent number: 7166623
    Abstract: Compounds of formula (I): or pharmaceutically acceptable salts or solvates thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors.
    Type: Grant
    Filed: October 16, 2002
    Date of Patent: January 23, 2007
    Assignee: Glaxo Group Limited
    Inventors: Richard Martyn Angell, Paul Bamborough, George Stuart Cockerill, Kathryn Jane Smith, Ann Louise Walker